Abstract
Inflammation plays a role at all stages of atherosclerosis. Neopterin, a pteridine mainly synthesized by activated macrophages, is a marker of inflammation, immune system activation and an active participant in cardiovascular disease. Measurement of neopterin levels may help follow the evolution of specific inflammatory conditions (e.g. viral infection, renal transplant rejection, systemic inflammatory diseases, nephritic syndrome and autoimmune diseases). Serum levels of neopterin are elevated also in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Moreover, plasma levels of this molecule might predict adverse cardiovascular events in patients with CAD, acute coronary syndromes or severe PAD. In addition, neopterin levels are related to the development of heart failure. We provide an updated overview on neopterin and, its links with CAD, left ventricular dysfunction, and PAD. We also describe its potential role in cardiac regenerative strategies with using bone marrow cells.
Keywords: Atherosclerosis, cardiovascular disease, inflammation, neopterin
Current Vascular Pharmacology
Title: Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Volume: 9 Issue: 2
Author(s): Salvatore De Rosa, Plinio Cirillo, Mario Pacileo, Gianluca Petrillo, Greta-Luana D'Ascoli, Fabio Maresca, Francesca Ziviello and Massimo Chiariello
Affiliation:
Keywords: Atherosclerosis, cardiovascular disease, inflammation, neopterin
Abstract: Inflammation plays a role at all stages of atherosclerosis. Neopterin, a pteridine mainly synthesized by activated macrophages, is a marker of inflammation, immune system activation and an active participant in cardiovascular disease. Measurement of neopterin levels may help follow the evolution of specific inflammatory conditions (e.g. viral infection, renal transplant rejection, systemic inflammatory diseases, nephritic syndrome and autoimmune diseases). Serum levels of neopterin are elevated also in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Moreover, plasma levels of this molecule might predict adverse cardiovascular events in patients with CAD, acute coronary syndromes or severe PAD. In addition, neopterin levels are related to the development of heart failure. We provide an updated overview on neopterin and, its links with CAD, left ventricular dysfunction, and PAD. We also describe its potential role in cardiac regenerative strategies with using bone marrow cells.
Export Options
About this article
Cite this article as:
De Rosa Salvatore, Cirillo Plinio, Pacileo Mario, Petrillo Gianluca, D'Ascoli Greta-Luana, Maresca Fabio, Ziviello Francesca and Chiariello Massimo, Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519372
DOI https://dx.doi.org/10.2174/157016111794519372 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Editorial
Current Hypertension Reviews Therapeutic Medical Hypothermia-A Multispecialty Approach
Recent Patents on Cardiovascular Drug Discovery COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Current Medicinal Chemistry Recent Achievements on Siderophore Production and Application
Recent Patents on Biotechnology Therapeutic Approaches Targeting Pathological Tau Aggregates
Current Pharmaceutical Design Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Copeptin as a Biomarker in Cardiac Disease
Current Topics in Medicinal Chemistry Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry